Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/51022
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yıldırım, Halil Cumhur | - |
dc.contributor.author | Kupik, Gülnihan Eren | - |
dc.contributor.author | Mustafayev, Teuta Zoto | - |
dc.contributor.author | Berber, Tanju | - |
dc.contributor.author | Yavuz, Berrin | - |
dc.contributor.author | Çetinayak, Oğuz | - |
dc.contributor.author | Akagündüz, Özlem | - |
dc.contributor.author | Bicakci, Beyhan Ceylaner | - |
dc.contributor.author | Arslan, Suheyla Aytac | - |
dc.contributor.author | Soykut, Ela Delikgoz | - |
dc.contributor.author | Gundog, Mete | - |
dc.contributor.author | Figen, Metin | - |
dc.contributor.author | Teke, Fatma | - |
dc.contributor.author | Canyilmaz, Emine | - |
dc.contributor.author | Birgi, Sumerya Duru | - |
dc.contributor.author | Duzova, Mursel | - |
dc.contributor.author | Igdem, Sefik | - |
dc.contributor.author | Abakay, Candan Demiroz | - |
dc.contributor.author | Atasoy, Beste | - |
dc.contributor.author | Kaydihan, Nuri | - |
dc.contributor.author | Parvizi, Murtaza | - |
dc.contributor.author | Uslu, Gonca Hanedan | - |
dc.contributor.author | Saginc, Halil | - |
dc.contributor.author | Akman, Fadime | - |
dc.contributor.author | Ozyar, Enis | - |
dc.date.accessioned | 2023-06-13T19:08:06Z | - |
dc.date.available | 2023-06-13T19:08:06Z | - |
dc.date.issued | 2023 | - |
dc.identifier.issn | 1043-3074 | - |
dc.identifier.issn | 1097-0347 | - |
dc.identifier.uri | https://doi.org/10.1002/hed.27333 | - |
dc.identifier.uri | https://hdl.handle.net/11499/51022 | - |
dc.description.abstract | BackgroundWe aimed to evaluate patients with nasopharyngeal carcinoma (NPC) in a nonendemic population. MethodsIn a national, retrospective, multicenteric study, 563 patients treated with intensity modulated radiotherapy at 22 centers between 2015 and 2020 were analyzed. ResultsMedian age was 48 (9-83), age distribution was bimodal, 74.1% were male, and 78.7% were stage III-IVA. Keratinizing and undifferentiated carcinoma rates were 3.9% and 81.2%. Patients were treated with concomitant chemoradiotherapy (48.9%), or radiotherapy combined with induction chemotherapy (25%) or adjuvant chemotherapy (19.5%). After 34 (6-78) months follow-up, 8.2% locoregional and 8% distant relapse were observed. Three-year overall survival was 89.5% and was lower in patients with age >= 50, male sex, keratinizing histology, T4, N3 and advanced stage (III-IVA). ConclusionsPatients with NPC in Turkey have mixed clinical features of both east and west. Survival outcomes are comparable to other reported series; however, the rate of distant metastases seems to be lower. | en_US |
dc.description.sponsorship | University Grants Commission (UGC), New Delhi [8- 4(57)/2015(MRP/NRCB]; UGC-DAE CSR Kolkata Centre | en_US |
dc.description.sponsorship | The author, Ashok K. Pathak, acknowledges financial assistance from the University Grants Commission (UGC), New Delhi (8- 4(57)/2015(MRP/NRCB)). Author, V. K. Singh is very thankful to UGC-DAE CSR Kolkata Centre for partial financial support. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.relation.ispartof | Head and Neck-Journal for the Sciences and Specialties of the Head and Neck | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | chemoradiotherapy | en_US |
dc.subject | EBV-DNA | en_US |
dc.subject | intensity-modulated radiotherapy | en_US |
dc.subject | nasopharyngeal carcinoma | en_US |
dc.subject | nonendemic | en_US |
dc.subject | Intensity-Modulated Radiotherapy | en_US |
dc.subject | Ajcc/Uicc Staging System | en_US |
dc.subject | Concurrent Chemoradiotherapy | en_US |
dc.subject | 8th Edition | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | Dna | en_US |
dc.subject | Validation | en_US |
dc.subject | Worldwide | en_US |
dc.subject | Outcomes | en_US |
dc.subject | Trials | en_US |
dc.title | A multicenter retrospective analysis of patients with nasopharyngeal carcinoma treated in IMRT era from a nonendemic population: Turkish Society for Radiation Oncology Head and Neck Cancer Group Study (TROD 01-001) | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 45 | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.startpage | 1194 | en_US |
dc.identifier.endpage | 1205 | en_US |
dc.department | Pamukkale University | en_US |
dc.authorid | ceylaner bıçakcı, beyhan/0000-0003-2509-6742 | - |
dc.authorid | Delikgoz Soykut, Ela/0000-0003-1225-8458 | - |
dc.authorid | Ozkaya Akagunduz, Ozlem/0000-0001-9733-774X | - |
dc.authorid | Zoto Mustafayev, Teuta/0000-0001-6029-1995 | - |
dc.authorid | yildirim, halil cumhur/0000-0002-1412-1933 | - |
dc.identifier.doi | 10.1002/hed.27333 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 57830411000 | - |
dc.authorscopusid | 57431969700 | - |
dc.authorscopusid | 57205744859 | - |
dc.authorscopusid | 36112827700 | - |
dc.authorscopusid | 57193654701 | - |
dc.authorscopusid | 14018946800 | - |
dc.authorscopusid | 16645046400 | - |
dc.authorwosid | ceylaner bıçakcı, beyhan/HJH-5904-2023 | - |
dc.authorwosid | Delikgoz Soykut, Ela/AEX-9110-2022 | - |
dc.identifier.pmid | 36854873 | en_US |
dc.identifier.scopus | 2-s2.0-85149269238 | en_US |
dc.identifier.wos | WOS:000940768500001 | en_US |
dc.institutionauthor | … | - |
dc.identifier.scopusquality | Q1 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
item.openairetype | Article | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.